-
Notable Transactions
Alex has worked with notable industry names such as Peloton Therapeutics, WuXi Apptec, and Enable Injections.
Dr. Alexander Key is a partner in the technology transactions practice of Wilson Sonsini Goodrich & Rosati, where he focuses on the representation of biotechnology, pharmaceutical, medical device, digital health, and other life science and high technology companies. Alex advises private and public companies, both domestic and international, on a broad range of partnering transactions, including the structuring and negotiation of licenses, collaborations, and procurement arrangements, as well as mergers and acquisitions. He has significant experience in novel therapeutic modalities and technologies, including AI-enabled target and drug discovery, next-generation medical devices and cellular and biological engineering. Alex regularly assists nonprofits with transactional and intellectual property matters, including The Buck Institute for Research on Aging, Fogarty Innovation, Stanford Biodesign and Biocom.
Alex was shortlisted as a finalist for “Licensing and Collaboration Attorney of the Year” by LMG Life Sciences Americas in 2025, and was named as a transactional “star” in 2024-2026.
Prior to joining the firm, Alex worked as an associate at Simpson, Thacher & Bartlett, where he focused on intellectual property transactions and litigation including Hatch-Waxman and patent infringement disputes.
Dr. Alexander Key is a partner in the technology transactions practice of Wilson Sonsini Goodrich & Rosati, where he focuses on the representation of biotechnology, pharmaceutical, medical device, digital health, and other life science and high technology companies. Alex advises private and public companies, both domestic and international, on a broad range of partnering transactions, including the structuring and negotiation of licenses, collaborations, and procurement arrangements, as well as mergers and acquisitions. He has significant experience in novel therapeutic modalities and technologies, including AI-enabled target and drug discovery, next-generation medical devices and cellular and biological engineering. Alex regularly assists nonprofits with transactional and intellectual property matters, including The Buck Institute for Research on Aging, Fogarty Innovation, Stanford Biodesign and Biocom.
Alex was shortlisted as a finalist for “Licensing and Collaboration Attorney of the Year” by LMG Life Sciences Americas in 2025, and was named as a transactional “star” in 2024-2026.
Prior to joining the firm, Alex worked as an associate at Simpson, Thacher & Bartlett, where he focused on intellectual property transactions and litigation including Hatch-Waxman and patent infringement disputes.
- J.D., Duke University School of Law, 2005Cum Laude; Board Member, Intellectual Property Law Society; Editor, Duke Environmental Law & Policy Forum
- Ph.D., Biomedical Sciences, University of New Mexico School of Medicine, 2002With Highest Distinction
- B.A., Economics and Philosophy, University of New Mexico, 1999With Highest Distinction
- Major in Economics, Cornell University
- Named as a finalist for LMG Life Sciences Americas’ “Licensing and Collaboration Attorney of the Year,” 2025
- Recognized as a “star” in licensing and collaboration transactions by LMG Life Sciences Americas, 2024-2026
- State Bar of California
- State Bar of New York
- J.D., Duke University School of Law, 2005Cum Laude; Board Member, Intellectual Property Law Society; Editor, Duke Environmental Law & Policy Forum
- Ph.D., Biomedical Sciences, University of New Mexico School of Medicine, 2002With Highest Distinction
- B.A., Economics and Philosophy, University of New Mexico, 1999With Highest Distinction
- Major in Economics, Cornell University
- Named as a finalist for LMG Life Sciences Americas’ “Licensing and Collaboration Attorney of the Year,” 2025
- Recognized as a “star” in licensing and collaboration transactions by LMG Life Sciences Americas, 2024-2026
- State Bar of California
- State Bar of New York
Recent Illustrative Transactions
- InSilico Medicine in license and collaboration arrangements with Takeda, Eli Lilly, the Menarini Group, Exelixis, Sanofi, EQRx, and Fosun Pharma
- Enable Injections in various license, development, and supply arrangements relating to Enable’s on-body device for the subcutaneous delivery of therapeutics, including with Sanofi, Roche, Viridian Therapeutics, Apellis, Sobi, Serina Therapeutics, Eledon Pharmaceuticals, and Incyte
- Nosis Biosciences in collaborations with Janssen and Daiichi Sankyo
- 4E Therapeutics in its acquisition by Eli Lilly
- LaNova Medicine in collaboration and license agreements with Merck, AstraZeneca, and Turning Point Therapeutics
- Circle Pharma in license and collaboration transactions, including with Boehringer Ingelheim and Pfizer
- Bolt Medical in its acquisition by Boston Scientific
- BioMap in a collaboration with Sanofi for the development of an AI-based biotherapeutic discovery platform
- Serina Therapeutics in a license arrangement with Pfizer applying Serina's proprietary poly(oxazoline) (POZ) technology to mRNA vaccines for the treatment or prevention of influenza
- BioMap in a collaboration with Sanofi for the development of an AI-based biotherapeutic discovery platform
- Serina Therapeutics in a license arrangement with Pfizer applying Serina's proprietary poly(oxazoline) (POZ) technology to mRNA vaccines for the treatment or prevention of influenza
- BioMap in a collaboration with Sanofi for the development of an AI-based biotherapeutic discovery platform
- Serina Therapeutics in a license arrangement with Pfizer applying Serina's proprietary poly(oxazoline) (POZ) technology to mRNA vaccines for the treatment or prevention of influenza
Recent Illustrative Transactions
- InSilico Medicine in license and collaboration arrangements with Takeda, Eli Lilly, the Menarini Group, Exelixis, Sanofi, EQRx, and Fosun Pharma
- Enable Injections in various license, development, and supply arrangements relating to Enable’s on-body device for the subcutaneous delivery of therapeutics, including with Sanofi, Roche, Viridian Therapeutics, Apellis, Sobi, Serina Therapeutics, Eledon Pharmaceuticals, and Incyte
- Nosis Biosciences in collaborations with Janssen and Daiichi Sankyo
- 4E Therapeutics in its acquisition by Eli Lilly
- LaNova Medicine in collaboration and license agreements with Merck, AstraZeneca, and Turning Point Therapeutics
- Circle Pharma in license and collaboration transactions, including with Boehringer Ingelheim and Pfizer
- Bolt Medical in its acquisition by Boston Scientific
- BioMap in a collaboration with Sanofi for the development of an AI-based biotherapeutic discovery platform
- Serina Therapeutics in a license arrangement with Pfizer applying Serina's proprietary poly(oxazoline) (POZ) technology to mRNA vaccines for the treatment or prevention of influenza
- BioMap in a collaboration with Sanofi for the development of an AI-based biotherapeutic discovery platform
- Serina Therapeutics in a license arrangement with Pfizer applying Serina's proprietary poly(oxazoline) (POZ) technology to mRNA vaccines for the treatment or prevention of influenza
- BioMap in a collaboration with Sanofi for the development of an AI-based biotherapeutic discovery platform
- Serina Therapeutics in a license arrangement with Pfizer applying Serina's proprietary poly(oxazoline) (POZ) technology to mRNA vaccines for the treatment or prevention of influenza
- Privacy Policy
- Terms of Use
- Accessibility